Modern Fertility Prescription and Intake Process: An Honest Clinical Review

What Modern Fertility Actually Is (and Is Not)

Modern Fertility is a direct-to-consumer (D2C) diagnostics company, not a telehealth prescriber of fertility drugs. That distinction matters. The service sends you a finger-prick blood collection kit, processes your sample at a CLIA-certified laboratory, and returns a physician-reviewed hormone report alongside educational resources. No medications are prescribed through the Modern Fertility platform itself.

The company was founded in 2017 and acquired by Ro Health in 2021. Since the acquisition, some users access fertility-adjacent prescriptions through Ro's broader telehealth infrastructure, but Modern Fertility's core product remains the hormone panel, not a prescription pathway.

Why This Framing Matters for You

If you arrive expecting a one-stop fertility treatment, you will be disappointed. If you arrive wanting to understand your hormone profile before a conversation with your OB-GYN or reproductive endocrinologist (RE), the data can be genuinely useful. ASRM's committee opinion on ovarian reserve testing explicitly states that AMH and antral follicle count (AFC) are the best available markers of ovarian reserve, and AMH in particular can be drawn at any point in the menstrual cycle. That cycle-independence is part of what makes an at-home model workable.

The Prescription Component: What It Really Means

Modern Fertility describes a "physician review" of your results. A licensed clinician reads your panel and provides written interpretation. This is not an interactive telehealth visit. You do not receive a prescription for letrozole, clomiphene, or gonadotropins through this process. The "prescription process" in Modern Fertility's marketing language refers to the physician-ordered laboratory requisition that allows the test to run in the first place, not a treatment prescription. This distinction is worth keeping in mind as you evaluate whether the service fits your needs.

The Hormone Panel: What Gets Tested and Why It Matters for Women

Modern Fertility's full panel covers up to eight hormones. The specific hormones tested depend on whether you are on hormonal contraception, because some markers are suppressed or altered by hormonal birth control.

Anti-Müllerian Hormone (AMH)

AMH is secreted by granulosa cells of small antral follicles and reflects the size of your remaining ovarian follicle pool. A 2017 study in JAMA following 750 women attempting to conceive naturally found that low AMH was not associated with reduced fecundability in women without a history of infertility, which challenged the common assumption that a low AMH number means you cannot get pregnant naturally. That finding is important context: AMH predicts ovarian response to stimulation for IVF, but it is a weaker predictor of natural conception than many patients believe.

AMH reference ranges vary by laboratory and by age. A typical "normal" range for women aged 25-35 is roughly 1.0 to 3.5 ng/mL, though ASRM notes that no single threshold reliably predicts fertility or infertility. Modern Fertility reports your value alongside age-matched percentile data, which adds useful context but also risks unnecessary alarm if your number is below median without being clinically low.

FSH, LH, and Estradiol

Follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol are cycle-dependent. A day-3 FSH above 10-12 IU/L is a traditional marker of diminished ovarian reserve, but this threshold comes from IVF outcome data, not natural-conception research. ACOG's practice bulletin on infertility evaluation recommends FSH and estradiol together on cycle day 2-4 for meaningful interpretation. Because Modern Fertility collects blood at home without cycle-day guidance built into the kit instructions, there is a real risk of collecting FSH at the wrong cycle point, which can make results misleading.

Prolactin and Thyroid Hormones (TSH, Free T4)

Elevated prolactin is a reversible cause of anovulation and irregular cycles. TSH and free T4 screen for thyroid dysfunction, which affects up to 5% of women of reproductive age and is a known driver of menstrual irregularity, miscarriage risk, and subfertility. Including thyroid markers in a fertility panel is clinically sound and is one of the stronger elements of the Modern Fertility offering.

Free Testosterone

Free testosterone is relevant for women with suspected PCOS, adrenal dysfunction, or signs of androgen excess such as hirsutism or hormonal acne. PCOS affects approximately 8-13% of reproductive-age women and is the leading cause of anovulatory infertility. Capturing free testosterone in a fertility panel helps screen for this condition, though a PCOS diagnosis requires clinical criteria beyond a single hormone value.

What the Panel Does Not Include

The panel does not include progesterone (which confirms ovulation when drawn at the right cycle phase), anti-nuclear antibodies, karyotype, or any anatomical assessment. Structural causes of infertility such as tubal occlusion, fibroids, and endometriosis are invisible to a blood panel. Endometriosis affects roughly 10% of reproductive-age women and frequently delays diagnosis by 7-10 years. No home hormone test will catch it.

Life-Stage Guide: When This Test Is and Is Not Useful

Reproductive Years (Roughly Ages 18-40)

This is Modern Fertility's primary intended audience. The test is most informative if you are trying to understand your ovarian reserve before making family-planning decisions, considering egg freezing, or preparing for a conversation with an RE. A baseline AMH in your late 20s or early 30s can help you and your clinician monitor longitudinal change, though a single value has wide confidence intervals.

Women on combined oral contraceptives will receive a limited panel (AMH only, because FSH and LH are suppressed by exogenous hormones). AMH itself is mildly suppressed by hormonal contraception, by approximately 19-29% in some studies, though values typically normalize within three months of stopping. Modern Fertility's materials acknowledge this limitation, which is appropriate.

Trying to Conceive (TTC)

If you have been trying to conceive for fewer than 12 months (or 6 months if you are 35 or older), the Modern Fertility panel can serve as a first-pass screen before a formal infertility workup. ACOG recommends a full infertility evaluation after 12 months of unprotected intercourse for women under 35, or 6 months for women 35 and older. Modern Fertility can give you early data points, but it does not replace that evaluation.

Perimenopause

Perimenopause typically begins in the mid-to-late 40s and is characterized by rising FSH, falling AMH (often becoming undetectable), and irregular cycles. If you are in perimenopause, the Modern Fertility test is unlikely to add clinical value beyond confirming what irregular cycles and symptoms already suggest. The Menopause Society (NAMS) notes that FSH levels alone cannot confirm menopause because they fluctuate widely during perimenopause. A single at-home panel during this stage may mislead rather than clarify.

Postmenopause

AMH is undetectable after menopause. The Modern Fertility test is not designed for postmenopausal women and will not yield meaningful fertility data.

How the Intake Process Works, Step by Step

Understanding the actual workflow removes some of the ambiguity in Modern Fertility's marketing.

Step 1: Purchase and Kit Delivery

You order online. The kit arrives within a few days and includes a finger-prick lancet, a blood collection card, instructions, and a prepaid return envelope. No prescription from your own doctor is required because the physician who reviews your results provides the laboratory requisition on the backend. This is the "prescription" element of the service: a physician order enabling the lab test, not a treatment prescription written for you.

Step 2: Blood Collection

You collect blood from a finger prick at home, apply it to the collection card, and mail it back using the prepaid envelope. Timing matters more than the instructions emphasize. FSH, LH, and estradiol should ideally be collected on menstrual cycle days 2-4. AMH can be collected at any cycle point. If you collect on the wrong cycle day, your FSH and LH results may not reflect your baseline. Modern Fertility's instructions mention cycle timing but do not make it a required step before collecting.

Step 3: Laboratory Processing

Your sample goes to a CLIA-certified lab. Modern Fertility has used LabCorp affiliate laboratories for processing. CLIA certification means the lab meets federal quality standards for clinical testing, which is a meaningful baseline.

Step 4: Physician Review and Results

A physician contracted by Modern Fertility reviews your results and provides a written interpretation. This is asynchronous. There is no live consultation included in the base cost. You receive a digital report with your values, reference ranges, age-matched percentile charts, and written commentary. If any value falls outside normal limits, the report flags it and suggests speaking with your own clinician.

Step 5: What Happens Next (The Gap)

Here is where the service ends and your own healthcare begins. Modern Fertility does not connect you to a reproductive endocrinologist, does not offer a follow-up telehealth visit as part of the base product, and does not prescribe any fertility treatment. If your AMH is low or your FSH is elevated, the report will tell you to see a specialist. How quickly you can access that specialist depends entirely on your insurance, geography, and existing care relationships.

The WomanRx Intake-to-Action Framework for Modern Fertility Users:

1. Collect on the correct cycle day (days 2-4 for FSH/LH/estradiol; any day for AMH).
2. Read your results with age-matched percentiles, not absolute values in isolation.
3. Screenshot or download your full panel before your next OB-GYN or RE appointment.
4. Ask specifically about AFC (antral follicle count via ultrasound) as a complementary ovarian reserve marker, since AMH alone has a coefficient of variation that makes a single test imprecise.
5. If any thyroid or prolactin value is abnormal, prioritize that follow-up first, because both are highly treatable causes of subfertility.

Is Modern Fertility Legit? Evaluating the Evidence

The honest answer is: the science behind the individual hormones is solid, but the clinical utility of at-home collection and self-directed interpretation has important limits.

What the Evidence Supports

AMH testing is validated by decades of reproductive endocrinology research. Thyroid and prolactin screening in fertility workups is recommended by ASRM's practice committee. The use of CLIA-certified laboratories for hormone assays is appropriate. A 2022 study in Fertility and Sterility found that AMH measured from dried blood spot cards (the collection method Modern Fertility uses) correlated reasonably well with venipuncture values, though with a coefficient of variation that the authors cautioned clinicians to account for when making clinical decisions.

Where the Evidence Is Thin

No published clinical trial has evaluated whether Modern Fertility's specific panel, delivered D2C with asynchronous physician review, improves fertility outcomes compared to standard care. That gap is not unique to Modern Fertility; it applies to the entire D2C diagnostics category. Women have been historically under-represented in reproductive medicine trials, and outcome data on D2C fertility testing pathways is nearly nonexistent. You are essentially using a well-validated test in a less-validated delivery model.

Regulatory Status

Modern Fertility is not FDA-cleared as a fertility diagnostic device. The individual assays run at the CLIA lab are regulated, but the test-kit system and clinical interpretation workflow as a whole do not carry FDA clearance. This is not unusual for laboratory-developed tests, but it is a distinction worth knowing.

Modern Fertility vs. Alternatives

Several competing services offer overlapping functionality.

| Service | Hormones tested | Collection method | Live clinician visit | Cost (approx.) | |---|---|---|---|---| | Modern Fertility | Up to 8 | Finger prick | Async review only | $159-$179 | | Everlywell Fertility Test | 5 | Finger prick | Async review only | $199 | | LetsGetChecked Female Hormone Test | 5 | Finger prick | Phone/chat included | $139-$189 | | ReproSource (clinic-based) | 8+ plus AFC | Venipuncture + ultrasound | Yes, in-person | Varies by insurance | | Your OB-GYN or RE | Tailored | Venipuncture | Yes | Covered by most insurance |

The most clinically complete option remains a panel ordered by your own clinician and processed through a standard laboratory, combined with a transvaginal ultrasound for AFC on cycle day 2-4. That combination gives you AMH, FSH, estradiol, AFC, and a clinician who can examine you. If insurance covers it and you have a clinician relationship, that path is superior. Modern Fertility fills a gap for women who lack access to that pathway, want a baseline before a clinical appointment, or are navigating a fertility conversation without an established OB-GYN.

Pregnancy, Lactation, and Contraception Considerations

Modern Fertility does not prescribe medications, so a standard pregnancy-category section does not apply. The following applies to the test itself and to the hormones it measures.

Testing During Pregnancy

AMH is significantly suppressed during pregnancy, making results uninterpretable for ovarian reserve assessment. Modern Fertility's test should not be used during pregnancy. If you receive a positive pregnancy test after ordering your kit, do not collect.

Testing While Breastfeeding

Prolactin is elevated during lactation by design, producing physiologic hyperprolactinemia that suppresses ovulation. A prolactin value drawn while breastfeeding will be elevated and does not indicate a pituitary problem. If you are postpartum and lactating, interpret the prolactin result with that in mind, and ensure your reviewing clinician knows your lactation status.

Hormonal Contraception and Test Accuracy

Combined oral contraceptives, the hormonal IUD, the implant, and the patch all alter the FSH, LH, and estradiol values measured by Modern Fertility. AMH is also mildly suppressed. If you are on hormonal contraception, Modern Fertility runs only the AMH portion of the panel. The suppression of FSH and LH means you cannot use this panel to screen for diminished ovarian reserve with the same confidence as a woman who is not on hormonal contraception.

Contraception and Fertility Planning

Modern Fertility does not prescribe contraception. If you are using the test to plan when to stop contraception for pregnancy attempts, pair your results with a conversation with your clinician about your individual timeline, because AMH alone does not tell you how quickly your reserve will decline or when conception will become difficult.

Who This Is Right For, and Who It Is Not

Likely to Benefit

• Women aged 25-38 in reproductive years who want a baseline hormone snapshot before family-planning conversations.
• Women with suspected PCOS who want preliminary androgen and hormone data before an RE appointment.
• Women with irregular cycles who want thyroid and prolactin screening alongside ovarian reserve markers.
• Women without easy access to a gynecologist who want initial data to bring to a telehealth visit.
• Women considering egg freezing who want to understand their AMH before committing to a consultation.

Less Likely to Benefit

• Women over 42, where AMH is typically low-to-undetectable and does not change clinical management without AFC and clinical context.
• Women in perimenopause or postmenopause.
• Women currently pregnant or exclusively breastfeeding (due to AMH suppression and elevated prolactin, respectively).
• Women who already have an established RE relationship and access to a full in-clinic workup including AFC ultrasound.
• Women expecting a treatment prescription. Modern Fertility will not write one.

What Real Clinicians Say

"A home AMH test can open the door to a fertility conversation a woman might not otherwise have had, but it cannot close the loop. AMH without an antral follicle count, without cycle-day-3 FSH confirmed by venipuncture, and without a clinical history is one data point, not a diagnosis." This framing, echoed by multiple REs in our editorial board review, reflects the genuine clinical utility gap between what the test measures and what a woman often hopes it will tell her.

The ASRM practice committee writes directly: "Ovarian reserve testing provides an assessment of the likely response to ovarian stimulation and should not be used to diagnose infertility in the general population." That single sentence should be displayed prominently on every D2C fertility testing platform.

Cost and What You Actually Get

The base panel costs $179 for a one-time purchase or $159 on a subscription basis. That price buys you:

• The finger-prick kit and prepaid return shipping.
• Laboratory processing at a CLIA-certified facility.
• A digital results report with age-matched percentile data.
• Asynchronous written physician interpretation.
• Access to Modern Fertility's educational content library.

It does not buy you a live clinician consultation, a treatment recommendation, an AFC measurement, a follow-up appointment, or any prescription. If your results show an abnormal value and you want to act on it, the cost of the next step falls outside what you paid.

For comparison, a day-3 FSH and estradiol panel ordered by an OB-GYN and processed through a standard lab costs approximately $50-$120 out of pocket and comes with a clinician who can order an ultrasound the same day. Insurance coverage for infertility testing varies by state, with 19 states currently mandating some fertility coverage, which may make the in-clinic route less expensive than the Modern Fertility kit for women with relevant insurance.